Ahmedabad: Corona Remedies Limited posted a 33% growth in its profit after tax (PAT) for FY 2026 which stood at Rs 199 crore, the company , which is headquartered in Ahmedabad, announced in a stock exchange filing. The company also posted a 17.3% rise in its annual revenues during the fiscal year which stood at Rs 1,403 crore.The company attributes the growth to brand-building initiatives coupled with operational efficiencies and portfolio expansion.During the year, it acquired Wokadine, marking its entry into the Rs 648-crore povidone-iodine market, funded through internal accruals. Corona Remedies also relaunched key brands in women’s health and cardiovascular therapies and set up a dedicated infertility segment team.The pharma company said Q4FY26 revenue rose 20.2% to Rs 353 crore.Nirav Mehta, MD and CEO, said, “The company’s focus on brand building, specialty segments like biosimilars and infertility and portfolio expansion through acquisitions continues to strengthen our competitive positioning.”
